Human pancreatic cancer fusion 2 (HPC2) 1-B3: A novel monoclonal antibody to screen for pancreatic ductal dysplasia

Terry K. Morgan, Karin Hardiman, Christopher L. Corless, Sandra L. White, Robert Bonnah, Henry Van De Vrugt, Brett C. Sheppard, Markus Grompe, Ediz F. Cosar, Philip R. Streeter

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


BACKGROUND. Pancreatic ductal adenocarcinoma is rarely detected early enough for patients to be cured. The objective of the authors was to develop a monoclonal antibody to distinguish adenocarcinoma and precancerous intraductal papillary mucinous neoplasia (IPMN) from benign epithelium. METHODS. Mice were immunized with human pancreatic adenocarcinoma cells and monoclonal antibodies were screened against a panel of archived pancreatic tissue sections, including pancreatitis (23 cases), grade 1 IPMN (16 cases), grade 2 IPMN (9 cases), grade 3 IPMN (13 cases), and various grades of adenocarcinoma (17 cases). One monoclonal antibody, human pancreatic cancer fusion 2 (HPC2) 1-B3, which specifically immunostained adenocarcinoma and all grades of IPMN, was isolated. Subsequently, HPC2 1-B3 was evaluated in a retrospective series of 31 fine-needle aspiration (FNA) biopsies from clinically suspicious pancreatic lesions that had long-term clinical follow-up. RESULTS. HPC2 1-B3 was negative in all 31 cases of chronic pancreatitis that were tested. In contrast, HPC2 1-B3 immunostained the cytoplasm and luminal surface of all 16 well- to moderately differentiated pancreatic ductal adenocarcinomas. It demonstrated only weak focal staining of poorly differentiated carcinomas. All high-grade IPMNs were found to be positive for HPC2 1-B3. The majority of low-grade to intermediate-grade IPMNs were positive (66% of cases). Immunostaining a separate series of pancreatic FNA cell blocks for HPC2 1-B3 demonstrated that the relative risk for detecting at least low-grade dysplasia (2.0 [95% confidence interval, 1.23-3.26]) was statistically significant (P = .002 by the Fisher exact test). CONCLUSIONS. To reduce the mortality of pancreatic cancer, more effective early screening methods are necessary. The data from the current study indicate that a novel monoclonal antibody, HPC2 1-B3, may facilitate the diagnosis of early pancreatic dysplasia.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalCancer Cytopathology
Issue number1
StatePublished - Jan 2013


  • Ductal adenocarcinoma
  • Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA)
  • Intraductal papillary mucinous neoplasm (IPMN)
  • Monoclonal antibody
  • Pancreas

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Human pancreatic cancer fusion 2 (HPC2) 1-B3: A novel monoclonal antibody to screen for pancreatic ductal dysplasia'. Together they form a unique fingerprint.

Cite this